---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-103773"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T13:51:36.325896+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organon Q2 2021 revenue $1.6B, net income $431M; declares inaugural $0.28 quarterly dividend

## Summary
- Q2 2021 revenue $1,595M (+5% as-reported; -1% ex-FX); Women's Health +19%, Biosimilars +43%, Established Brands -4%.
- Net income from cont. ops. $431M ($1.70 diluted EPS); adjusted net income $437M ($1.72 adj. diluted EPS); adjusted EBITDA $627M.
- Board declares quarterly dividend of $0.28/share, payable Sept 13, 2021 to holders of record Aug 23, 2021.
- Full-year 2021 guidance affirmed: revenue $6.1B-$6.4B, adjusted EBITDA margin 36%-38%, interest ~$400M.
- Cash and equivalents $730M, debt $9,348M, net debt $8,618M as of June 30, 2021.

## SEC filing metadata
- accession: 0001104659-21-103773
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465921103773/0001104659-21-103773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465921103773/tm2124441d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-103773
- JSON: https://secwatch.observer/filing/0001104659-21-103773.json
- Plain text: https://secwatch.observer/filing/0001104659-21-103773.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.